Enterprise Value
55.12M
Cash
320.7M
Avg Qtr Burn
N/A
Short % of Float
4.44%
Insider Ownership
1.54%
Institutional Own.
23.79%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Icosapent Etheyl (generic Vascepa) Details Triglycerides, Heart disease, Cardiovascular disease | Approved Update | |
Vascepa (icosapent ethyl) Details Triglycerides, Heart disease, Cardiovascular disease | Approved Quarterly sales | |
Vascepa (icosapent ethyl) Details Infectious disease, COVID-19 | Failed Discontinued |